Regulatory Focus™ > News Articles > In Focus: Doing Business in Asia

In Focus: Doing Business in Asia

Posted 01 February 2009 | By Mukesh Kumar, PhD 

Asia shines as a beacon of hope in an era when increasing development costs, shrinking pipelines, decreasing revenues and more-demanding clinical trials dominate discussions in the pharmaceutical industry. A recent report from the PricewaterhouseCooper's Health Research Institute,1 projects Asia to be the "Land of Golden Opportunities" that provides high-quality, inexpensive labor, and an increasingly favorable market for pharmaceuticals. Similar projections have been made by other financial and industry experts.2,3

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe